Asian Pacific Journal of Cancer Prevention

  • 제13권10호
  • /
  • Pages.5033-5036
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Clinical Implications of p57KIP2 Expression in Breast Cancer

  • Xu, Xiao-Yin (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University) ;
  • Wang, Wen-Qian (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University) ;
  • Zhang, Lei (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University) ;
  • Li, Yi-Ming (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University) ;
  • Tang, Miao (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University) ;
  • Jiang, Nan (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University) ;
  • Cai, Shou-Liang (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University) ;
  • Wei, Liang (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University) ;
  • Jin, Feng (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University) ;
  • Chen, Bo (Department of Surgical Oncology and Department of Breast Surgery, the First Hospital of China Medical University)
  • 발행 : 2012.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To study the relationship between expression of $p57^{KIP2}$ and prognosis and other clinicopathological parameters in invasive breast cancers. Methods: We assessed the expression of $p57^{KIP2}$ in 89 cases of invasive breast cancer and 20 cases of normal breast tissue by immunohistochemical methods and analyzed the results with SPSS software (ver. 16.0). Result: The positive expression rates of $p57^{KIP2}$ protein in the invasive breast cancers and surrounding normal tissue were 30.3% (27/89) and 65% (13/20), respectively. Cases with no $p57^{KIP2}$ expression exhibited a significantly higher post-operative distant metastasis rate than those with $p57^{KIP2}$ expression (37.9% vs. 14.8%; P = 0.01). DFS analysis showed that $p57^{KIP2}$-/C-erbB-2+ tumors also exhibited a significantly higher post-operative distant metastasis rate than the other groups (66.7% vs. 29.2%; P = 0.007), as did $p57^{KIP2}$-/p53+ tumors (64.3% vs. 22.7%; P = 0.001). Survival analysis revealed that $p57^{KIP2}$ was associated with breast cancer-specific survival overall (P = 0.045, log-rank test). Subgroup analysis demonstrated that individuals with $p57^{KIP2}$-/C-erbB-2+tumors experienced significantly worse post-operative survival than those with $p57^{KIP2}$-/C-erbB-2- or other tumors (P = 0.006, log-rank test). $p57^{KIP2}$-/p53+ tumors were associated with significantly worse post-operative survival than $p57^{KIP2}$-/p53- or other tumors (P = 0.001, log-rank test). Cox regression analysis showed that $p57^{KIP2}$ was a non-independent prognostic factor for breast cancer (P = 0.303). Conclusions: $p57^{KIP2}$ is expressed at low levels in invasive breast cancer and is associated with better overall survival rate and disease-free survival in breast cancer patients, but it was a non-independent prognostic factor for breast cancer. Thus, the connection between $p57^{KIP2}$/p53 and $p57^{KIP2}$/C-erbB-2 may provide biomarkers for breast cancer.

키워드

참고문헌

  1. Buiting K, Kanber D, Horsthemke B, et al (2010). Imprinting of RB1( the new kid on the block). Brief Funct Genomics, 9, 347-53. https://doi.org/10.1093/bfgp/elq014
  2. De P, Smith BR, Leyland-Jones B (2010). Human epidermal growth factor receptor 2 testing: where are we? J Clin Oncol, 28, 4289-92 https://doi.org/10.1200/JCO.2010.29.5071
  3. Duman-Scheel M, Weng L, Xin SJ, et al (2002). Hedgehog regulates cell growth and proliferation by inducing cyclin D and cyclin E. Nature, 417, 299-304. https://doi.org/10.1038/417299a
  4. Eddy AA (1996). Expression of genes that promote renal interstitial fibrosis in rats with proteinuria. Kidney Int, 54, S49-54.
  5. Gudmundsson J, Barkardottir RB, Eiriksdottir G, et al (1995). Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. Brit J Cancer, 72, 696-701. https://doi.org/10.1038/bjc.1995.396
  6. Guran S, Bahce M, Beyan C, Korkmaz K, Yalcin A (1998). P53, p15INK4B, p16INK4A and p57KIP2 mutations during the progression of chronic myeloid leukemia. Haematologia (Budap), 29, 181-93.
  7. Hatada I, Inazawa J, Nakayama M, et al (1996). Genomic imprinting of human P57-KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet, 5, 783-8. https://doi.org/10.1093/hmg/5.6.783
  8. Karnik P, Paris M, Williams BRG, T, et al (1998). wo distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastatsis. Hum Mol Genet, 7, 895-903. https://doi.org/10.1093/hmg/7.5.895
  9. Kavanagh E, Joseph B (2011). The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta, 1816, 50-6.
  10. Koepp DM, Schaefer LK, Ye X, et al (2001). Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw 7 ubiquitin ligase. Science, 294, 173-7. https://doi.org/10.1126/science.1065203
  11. Kondo M, Matsuoka S, Uchida K, et al (1996). Selective maternal-allele loss in human lung cancers of the maternally expressed P57-KIP2 gene at 11p15.5. Oncogene, 12, 1365-8.
  12. Lichy JH, Zavar M, Tsai MM, et al (1998). Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast. Am J Pathol, 153, 271-8. https://doi.org/10.1016/S0002-9440(10)65568-X
  13. Li Y, Millikan RC, Newman B, et al (1999). P57(KIP2) polymorphisms and breast cancer risk. Hum Genet, 104, 83-8. https://doi.org/10.1007/s004390050914
  14. Matsuoka S, Edwards MC, Bai C, et al (1995). $P57^{KIP2}$, a structurally distinct member of the p21CIP Cdk inhibitor family is a candidate tumor suppressor gene. Gene Dev, 9, 650-62. https://doi.org/10.1101/gad.9.6.650
  15. Matsuoka S, Thompson J, Edwards M, et al (1996). Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor,P57-KIP2, on chromosome 11p15. P Natl Acad Sci USA, 93, 3026-30. https://doi.org/10.1073/pnas.93.7.3026
  16. Procter M, Suter TM, de Azambuja E, et al (2010). Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol, 28, 3422-8. https://doi.org/10.1200/JCO.2009.26.0463
  17. Seizinger B, Deimling A (1991). Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet, 58, 1080-96. https://doi.org/10.1159/000133722
  18. Tokino T, Urano T, Furuhata T, et al (1996). Characterization of the human $P57^{KIP2}$ gene:alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Hum Genet, 97, 625-31. https://doi.org/10.1007/BF02281873
  19. Zhang P, Liegeois N, Wong C, et al (1997). Altered cell differentiation and proliferation in mice lacking P57-KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature, 387, 151-63. https://doi.org/10.1038/387151a0

피인용 문헌

  1. EGR1 decreases the malignancy of human non-small cell lung carcinoma by regulating KRT18 expression vol.4, pp.1, 2014, https://doi.org/10.1038/srep05416
  2. Breast cancer risk and imprinting methylation in blood vol.7, pp.1, 2015, https://doi.org/10.1186/s13148-015-0125-x
  3. Expression is Associated with Poor Prognosis in Human Breast Carcinoma vol.9s1, pp.1178-2234, 2015, https://doi.org/10.4137/BCBCR.S30101
  4. Role of P57KIP2 Immunohistochemical Expression in Histological Diagnosis of Hydatidiform Moles vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2061
  5. Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells vol.389, pp.12, 2016, https://doi.org/10.1007/s00210-016-1292-9
  6. ) in the early mouse placenta vol.83, pp.5, 2016, https://doi.org/10.1002/mrd.22637
  7. and involving in p-p38 MAPK and NF-κB pathways pp.07302312, 2019, https://doi.org/10.1002/jcb.27680